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ABSTRACT 
IN VIVO SIGNIFICANCE OF THE MDM4 AND P73 INTERACTION  
DURING DEVELOPMENT AND TUMORIGENESIS 
 
Mehrnoosh Tashakori, M.D. 
Supervisory Professor: Guillermina Lozano, Ph.D. 
 
 
The tumor suppressor protein p53 is negatively regulated by Mdm4 
protein. The significance of such regulation was determined from mouse models. 
Mdm4-deficient mice are embryonic lethal at E7.5 in a p53-dependent manner. 
p73, a member of the p53-family, is a transcription factor with tumor suppressor 
activity. In vitro studies show that Mdm4 binds to p73 and, further, 
comprehensive biochemical studies revealed that Mdm4 has higher affinity for 
p73 than p53. However, little is known about the significance of the Mdm4 and 
p73 interaction in vivo. This study aimed to elucidate the biological 
consequences of this interaction during embryogenesis and tumorigenesis using 
genetic mouse models.  
My study revealed that p73 loss does not rescue the Mdm4-deficient 
embryonic lethality, indicating that unrestricted p53 activity leads to the 
	   vii	  
phenotype. Furthermore, loss of p73 does not rescue the runted phenotype of 
Mdm4∆2/∆2 p53+/− embryos. These findings underscore that unrestricted p53 
activity, even at the haploid level, suffices to cause embryonic lethality.  Given 
the prominent roles of Mdm4 and p73 in developing brain, examining the 
importance of their interaction in this organ was noteworthy. Mdm4-deficiency in 
the brain causes porencephaly and late gestational embryonic lethality. This 
phenotype is rescued by deletion of p53. My work depicted that loss of p73 does 
not rescue the porencephaly phenotype at E14.5. However, interestingly, in the 
absence of Mdm4, p73 is transcriptionally active and possibly contributes to the 
vigorous senescent and apoptotic phenotype of p53 in embryonic brain. 
Since overexpression of Mdm4 and loss of p73 have been implicated in 
tumor development, I monitored a cohort of mice comprising Mdm4Tg15 p73+/−, 
Mdm4Tg15, p73+/− and wild type mice. While no survival differences were 
observed, Mdm4Tg15 p73+/− mice had increased incidence of lymphoma and brain 
tumors as well as advanced stage lymphoma with extensive dissemination 
compared to Mdm4Tg15 mice. These observations suggest that increased Mdm4 
and p73 haploinsufficiency cooperate in tumorigenesis. Combined, this study 
suggests that the Mdm4-p73 axis is not as significant as the Mdm4-p53 pathway 
during embryogenesis and tumor development.  
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CHAPTER 1. INTRODUCTION 
 
The p53 protein family  
 
The p53 protein family consists of three transcription factors, p53, p63 and 
p73. Having a common ancestor (1), the proteins in this family have substantial 
structural homology; each contains an N-terminal transactivation domain (TAD), a 
central DNA-binding domain (DBD) and a C-terminal oligomerization domain (OD). 
Such homology results in functional similarities, as evidenced by induction of 
apoptosis and cell cycle arrest in response to DNA damage (2). However, these 
genes also have very distinct functions as a result of exposure to different selection 
pressures during evolution. While p53 functions as the guardian of genome and 
maintains genome integrity, both p63 and p73 play more prominent roles during 
development (1-3).  
 
p53, the guardian of genome 
 
Since its discovery in 1979, p53 has been extensively studied in the field of 
cancer research. p53, well known as the “guardian of genome” (3) and the “cellular 
gatekeeper” (4), is altered in the majority of human tumors (3). This alteration can be 
through mutation or deletion of the p53 gene itself, or its functional inactivation via 
upregulation of its negative regulators, Mdm2 and Mdm4 (5).  
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p53 structure 
The human p53 gene is mapped to chromosome 17p13.1. It has 11 exons, 
which encode 393 amino acids for the full-length isoform of the p53 protein (6). Thus 
far, the structural analyses on p53 revealed that this protein has five main functional 
domains (Figure 1).  
The N-terminal region of p53 (1-101 aa) consists of an acidic TAD and a 
proline-rich region (7). The TAD interacts with various proteins, such as components 
of transcription machinery (8, 9), the transcriptional coactivators such as p300/CBP 
(10, 11) and p53 negative regulators, MDM2 and MDM4 (12-14). The TAD is 
subdivided to two subdomains, TAD1 (amino acids 1-42) and TAD2 (amino acids 
43-63) (7, 15). TAD1 has critical residues (Leu-22 and Trp-23) which determine the 
strength of its binding to the TATA-binding protein (TBP) and consequently control 
the rate of transcription (7). Moreover, these residues are necessary for MDM2 
interaction with p53, which results in concealing of the TAD and inhibition of p53 
activity (16). TAD2 also plays a role in activation of various p53 target genes (1); 
however, if TAD2 is mutated, TAD1 can compensate for normal transactivation of 
p53 (17). 
The proline-rich region has PXXP motifs, suggestive of mediating protein-
protein interactions. However, mouse models reveal that this region has structural 
rather than functional role. The complete deletion of proline-rich domain alters the 
p53 structure sufficiently to disrupt its function in mice, whereas mutations in this 
region are dispensable for tumor suppressor activity of p53 in vivo (18). 
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The central core of p53 (amino acids 102-292) comprises the DBD that 
recognizes the specific DNA sequence in the regulatory region of p53 target genes 
(19). Most cancer-related p53 mutations are found in this region, highlighting the 
significance of this domain in p53 tumor suppressor activity. These mutations alter 
either the ability of p53 to bind the target DNA sequence (DNA contact mutations) or 
the structure of the p53 DBD (conformational mutations) (20).  
The C-terminal region of p53 contains the OD (also known as tetramerization 
domain) (amino acids 324-355) and a basic, lysine-rich domain (amino acids 356-
393). Since p53 is active as a tetramer, the presence of tetramerization domain is 
essential for binding to DNA with high affinity (21). Moreover, the basic region is 
essential for p53 stability and its sequence-specific DNA binding (22).  
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Figure 1. Schematic representation of domain structure of p53. From the N-terminus 
to the C-terminus: transactivation domain 1 (TAD1), transactivation domain 2 
(TAD2), the proline-rich (PR) region, the central DNA binding domain (DBD), the 
oligomerization domain (OD) and the basic, lysine-rich domain (Basic). Numbers at 
the bottom indicate the approximate position of residues at the beginning and the 
end of each domain. 
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p53 functions 
In response to any cellular stress or damage that threatens the integrity of 
genome, p53 is activated via protein stabilization and post-translational 
modifications. Various stressors activate p53 in different ways. For instance, upon 
DNA damage due to ionizing radiation, p53 is activated by two kinases, ATM (Ataxia 
Telangiectasia mutated) and Chk2, whereas in response to oncogene activation 
such as Ras or Myc, p14ARF plays a role in stabilization of p53 (5). p53 tetramers 
bind to p53 response elements in the promoters of p53 target genes. These specific 
DNA sequences are classically defined as two copies of the 10 base pair motif 
RRRCWWGYYY (R: purine, W: adenine or thymine, Y: pyrimidine) separated by 0-
13 base pairs (19). A myriad of genes have been identified to be p53 transcriptional 
targets and mediate various p53 functions, such as p21, GADD45 and 14-3-3σ for 
cell cycle arrest, p21, PAI1 and PML for senescence, NOXA, PUMA and BAX for 
apoptosis (5, 23-25)  (Figure 2).  
The fate of cells due to p53 activation depends on cell type, external 
environment, the type and level of stress. In response to irreparable damages, p53 
induces irreversible apoptosis and senescence, whereas in minor insults, p53 
mediates cell cycle arrest and DNA repair to allow cells to repair damage and revert 
back to normal state (23, 26). p53 mediates several other protective mechanisms to 
maintain genome stability, such as expression of antioxidants (27), inhibition of 
glycolysis as well as promotion of oxidative stress (28) and autophagy (29, 30) 
(Figure 2). 
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Figure 2. p53 functions. In response to a wide range of cellular stress, such as DNA 
damage, oncogene activation, and oxidative stress, p53 regulators stabilize and 
activate p53 through post-translational modification. Activated p53 exerts its tumor 
suppressor function via upregulation of a plethora of target genes involved in 
apoptosis, cell cycle arrest, senescence, autophagy, DNA repair and metabolism, to 
name but a few. In unstressed condition, several negative regulators have been 
identified that dampened p53 levels and activity, including MDM2, MDM4, PIRH2, 
COP1 and TRIM24, to name a few. 
 
Page | 7  
 
 
p53 regulators 
As an unstable protein with the half-life of less than 20 minutes (31, 32), p53 
levels in unstressed cells are controlled by the rate of its degradation (5). Several 
post-translational modifications contribute to p53 stability and activity, including but 
not limited to phosphorylation, acetylation, ubiquitination and sumoylation (33). For 
instance, under physiological conditions, Mdm2 binds to the N-terminus of p53 and 
mediates p53 degradation by ubiquitination. Upon stress, such as DNA damage, 
phosphorylation of multiple amino acids in the N-terminus of p53 results in 
dissociation of Mdm2 and recruitment of transcriptional coactivators such as 
p300/CBP. Acetylation of the C-terminus of p53 by p300/CBP further assures the 
exclusion of Mdm2 and the engagement of the other components of transcriptional 
machinery (11, 33).  
Mdm2 is not the only enzyme which degrades p53. It has been shown that 
restored p53 in the Mdm2-null background degrades, albeit at a slower rate (34, 35). 
To date, a number of p53 regulators, which modulate p53 protein level, have been 
identified. For instance, Pirh2, Trim24 and Cop1, like Mdm2, are RING-type E3 
ubiquitin ligases that regulate p53 levels through uniquitination-mediated 
proteasomal degradation (Figure 2).  
Another mechanism by which p53 is controlled under physiological conditions 
is via blocking of its TAD. Negative regulators such as Mdm2 and Mdm4 bind to the 
TAD of p53 and by physical masking of this domain inhibit p53 transcriptional activity 
(Figure 2).  
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Among all negative regulators of p53, genetic mouse studies highlight that 
Mdm2 and Mdm4 are master regulators of p53 at least during development and 
homeostasis, as evidenced by the early embryonic lethality of Mdm2- and Mdm4-
deficient mice due to extensive p53 activity, a phenotype that was not observed 
upon deletion of other negative regulators of p53 (36-38).  
 
Significance of p53 regulation and its gene dosage  
Several studies and multiple mouse models have elucidated the importance 
of p53 gene dosage during tumorigenesis and survival. A comprehensive 
comparison of various p53 mouse models expressing different levels of p53 
revealed that expression of only 7% of wild type p53 in p53neo/− mice strikingly 
increases survival and shifts tumor spectrum compared to p53−/− mice (39).  In vivo 
genetic studies have shown that changes in the level of p53 regulators also affect 
the tumor phenotype. Both Mdm2 and Mdm4 transgenic mice develop spontaneous 
tumors and the main proposed oncogenic effect of these overexpressed proteins is 
through inhibiting p53 function (40, 41). The Mdm2SNP309G/G mice harboring a 
regulatory polymorphism of the Mdm2 gene also succumbs to tumors. This tumor-
prone mouse model with slightly higher level of Mdm2 emphasizes how a subtle 
change in a negative regulator of p53 dampens the p53 pathway and increases 
tumor susceptibility (42). Conversely, deletion of one allele of Mdm2 or Mdm4 
combined with transgenic expression of Myc oncogene or loss of tumor suppressor 
Rb extends survival of mice or decreases tumor burden, highlighting the protective 
effect of increasing p53 level (43-45).  
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Mdm4, the master regulator of p53 
 
Mdm4 identification  
 Some years after identification of Mdm2 as a binding partner and inhibitor of 
p53 (46, 47), a cDNA clone was isolated through screening of 16-day-old whole 
mouse embryo cDNA expression library with radiolabeled p53 protein. Since the 
construct had a high homology to Mdm2, at both the DNA and protein level, it was 
called Mdmx (also known as Mdm4) (48). The co-expression of p53 and Mdm4 in 
mammalian cells followed by immunoprecipitation showed that the two proteins 
interact in cells. Moreover, this association inhibited the transcriptional activity of 
p53, indicating that Mdm4 most probably interacted with the N-terminal region of p53 
(48). By fluorescent is situ hybridization (FISH), the Mdm4 gene was later mapped to 
chromosome 1 (region F-G) (49). A year later, MDM4, the human homolog of Mdm4, 
was identified with 90% similarity to murine Mdm4 and mapped to chromosome 
1q32 (49). The expression analysis of both human and mouse Mdm4 showed that 
they are ubiquitously expressed in all tissues. The highest level of Mdm4 is observed 
in thymus (48, 49).  
 
Mdm4 structure 
Human Mdm4 gene is mapped in chromosome 1q32.1. It comprises 11 exons 
with the first ATG start codon in the second exon (48) and encodes MDM4 protein 
with 490 amino acids. Like Mdm2, Mdm4 protein has three conserved domains: p53-
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binding domain at the N-termini, Acidic and Zinc-finger domains in the center and 
the Really Interesting New Gene (RING) finger domain at C-termini (Figure 3).  
The p53-binding domains in both MDM proteins are highly homologous with 
53.6% sequence similarity. Interestingly, the specific residues of this region, which 
are essential in p53 binding, are completely conserved in MDM2 and MDM4 (50). 
However, the X-ray crystallographic structures of TA domain of p53 and p53-binding 
domain of MDM4 depicted some variations between MDM2 and MDM4 binding to 
p53.  For instance, the central hydrophobic cleft of MDM4 on which the TA domain 
of p53 binds is smaller due to protrusion of the side chains of two MDM4 residues 
(Met53 and Tyr99) into the binding pocket (51). The observation that Nutlin-3a, a 
small molecule that disrupts the MDM2-p53 interaction, has lower potency in 
abrogating the MDM4-p53 complex further highlights the difference between the 
p53-binding domains of the  two MDM proteins. 
Another domain with high homology (53.2%) between MDM2 and MDM4 is 
the C-terminal RING-finger domain. However, unlike MDM2, the MDM4 RING 
domain does not possess E3 ubiquitin ligase activity (14). Nonetheless, the MDM4 
RING domain is essential for the Mdm2-Mdm4 heterodimerzation (52), MDM2 
stability and consequently p53 degradation by the MDM2 ubiquitin ligase activity (53, 
54) (Figure 2). Interestingly, the MDM2-MDM4 hetero-RING complexes are more 
common than the MDM2 homo-RING complex in vivo and exert a higher E3 
ubiquitin ligase activity (53). The importance of this domain is further strengthened 
by genetic mouse models. Disruption of the Mdm4 RING domain by either deletion 
or point mutation is embryonic lethal at E9.5. Both phenotypes are rescued by 
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concomitant deletion of p53, indicating the enhanced activity of p53 in the absence 
of MDM4 RING domain (32, 55).  
Although MDM4, unlike MDM2, does not have a canonical nuclear 
localization signal (NLS), a potential NLS within the RING finger domain has been 
suggested that contains basic amino acids (RRLKK) and, upon DNA damage, plays 
a role in nuclear translocation of MDM4 (50). Another study has shown that p53 and 
Mdm2 also play roles in shuttling Mdm4 into the nucleus upon DNA damage (56). 
The functions of two domain in the central region of MDM4, the zinc finger 
domain with high similarity to MDM2, and acidic domain with no significant homology 
to MDM2, remain largely unclear (57).  
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Figure 3. Schematic representation of Mdm2 and Mdm4 structure. The functional 
domains are highlighted. The p53-binding domain, zinc finger and RING finger 
domain are well conserved. The percentage homology shared between these 
domains is indicated.   
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Regulation of Mdm4 
a. Regulation of Mdm4 at transcription level 
Although Mdm4 is not induced by p53, recent studies have shown that Mdm4 
expression correlates to Mdm4 promoter activity and mRNA levels (58). A cluster of 
transcription binding sites in the promoter of Mdm4 (c-Ets-1, Elk-1 and Aml-1) has 
been recognized to be critical for increased Mdm4 expression in tumor cell lines.  
Moreover, mitogenic signaling through the Ras/Raf/MEK/ERK signaling pathway 
regulates Mdm4 expression at the mRNA transcription level via increased binding of 
Est-1 and Elk-1 to the Mdm4 promoter (58). The observations that MDM4 protein 
levels correlate with mRNA level in tumor cells and that the half-life of Mdm4 protein 
does not increase upon using MG132 (proteasome inhibitor) in unstressed cells (59), 
signify that, under physiologic conditions, Mdm4 expression is controlled at the 
transcription level.  
 
b. Regulation of Mdm4 at the post-transcriptional level 
MDM4 has five alternative splicing variants, which have been studied in detail 
for their effect on p53 inhibition. It has been proposed that the ratio of these splice 
variants to the full-length Mdm4 is of prognostic significance for cancer patients (60).  
MDM4-S is an MDM4 truncated protein as a result of a deletion in exon 6 and 
creation of a stop codon in exon 7 which shifts the reading frame. Consequently, this 
variant contains only the p53-binding domain and is suggested to bind to p53 and 
inhibit its activity stronger than full-length MDM4 (61). The overexpression of MDM4-
S transcript has been observed in primary soft tissue sarcomas and suggested as a 
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critical prognostic factor in these tumors (62). A subset of papillary thyroid 
carcinomas with wild type p53 has also been found to have MDM4-S overexpression 
(63). Another MDM4 variant, MDM4-221, was also observed in this tumor group 
whereas, interestingly, the full-length MDM4 level was significantly decreased in 
these tumors (63). 
The other two splicing variants, MDM4-A and MDM4-G, were identified in 
C233A cervical cancer cell lines. MDM4-A lacks the acidic domain due to deletion of 
exon 9 and MDM4-G lacks the p53-binding domain due to deletion of exons 3-6. 
Both forms inhibit p53 activity and stabilize MDM2, however, their physiologic 
function remains unclear (64).  
MDM4-Alt1 and MDM4-Alt2 transcripts are produced at various doses and 
times in response to DNA damage. MDM4-Alt1, similar to MDM4-S, has the p53-
binding domain and binds and represses p53 activity whereas MDM4-Alt2 lacks this 
domain and possibly stabilizes p53 by disrupting its binding to MDM2 (65).  
 
c. Regulation of Mdm4 at the post-translational level 
Several post-translational modifications have been characterized for MDM4 
including phosphorylation and ubiquitination, which result in either activation or 
repression of p53 activity.  
Phosphorylation of MDM4 at Ser367 by AKT kinases stabilizes MDM4, which 
in turn stabilizes MDM2 and inhibits p53 (66). Moreover, phosphorylation of MDM4 
at S289 by Casein kinase 1α (CK1 α) also results in inhibition of p53 by increasing 
MDM4 affinity for p53 (67). Upon genotoxic stress, c-Abl phosphorylates MDM4 at 
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Y99, which causes a conformational change that impairs the MDM4-p53 interaction 
and thus activates p53 (68).  
In response to DNA damage, the C-terminal of MDM4 is phosphorylated by 
ataxia-telangiectasia mutated (ATM) at S403 (69) and Checkpoint kinase 2 (Chk2) at 
S342 and S367 (70). Such phosphorylation in or close to the RING domain, along 
with other DNA damage-induced modifications of MDM2, reduce the MDM4 affinity 
for deubiquitylating enzyme HAUSP (71, 72) and leads to ubiquitination and 
degradation of MDM4 by MDM2 (73). Consequently, upon MDM4 degradation, 
MDM2 is destabilized and degraded and p53 is activated. 
MDM4 is also SUMOylated at K254 and K379 (74); however, the significance 
of these modifications remains unclear. 
 
d. Regulation of Mdm4 by Localization   
Under physiologic conditions, Mdm4 is localized in the cytoplasm and 
cooperates with MDM2 to inhibit p53 activity by promoting cytoplasmic localization of 
p53 (75). Upon DNA damage, p53 and MDM2 induce MDM4 nuclear translocation 
through complex formation. Further, nuclear MDM4 regulates p53 by blocking 
MDM2-mediated nuclear export of p53 and inhibiting MDM2-mediated p53 
ubiquitination (56, 76). In addition, a fraction of MDM4 localizes at the mitochondria 
and acts as a scaffold for the p53 and Bcl-2 interaction and, consequently, promotes 
apoptosis (77). 
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Mdm4 regulatory functions 
a. Significance of Mdm4 in regulating of p53 and lessons from animal models 
Similar to Mdm2, Mdm4 is a bona fide regulator of p53 during embryonic 
development, DNA damage and physiological conditions. The Mdm2-null mice die at 
embryonic day (E) 3.5 prior to implantation while Mdm4-deficient mice arrest at pre-
gastrulation and die at E7.5. These embryonic lethal phenotypes are due to 
apoptosis and cell cycle arrest, respectively, and both are completely rescued by 
deletion of p53 (78-80).  
Multiple tissue-specific and cell type-specific studies identified distinct and 
independent roles of Mdm2 and Mdm4 in regulating p53. While Mdm2 loss in 
cardiomyocytes is embryonic lethal at E13.5 due to apoptosis (80), mice with Mdm4-
deficient cardiomyocytes are viable but have a shortened life span (median survival 
of 234 days) due to apoptosis in cardiomyocytes and consequent dilated 
cardiomyopathy (81). Deletion of either Mdm2 or Mdm4 in neural progenitor cells of 
mouse is embryonic lethal. However, their phenotypes and p53-dependent 
mechanisms are different. Mdm2 loss in the brain results in hydranencephaly 
(absence of the brain’s cerebral hemispheres) due to apoptosis, whereas Mdm4 
deficiency causes porencephaly (presence of a cavity or cyst within the cerebral 
hemisphere) due to both apoptosis and cell cycle arrest. Both phenotypes are lethal 
at E12.5 and E17.5, respectively, and rescued by deletion of p53. Interestingly, 
concomitant deletion of Mdm2 and Mdm4 in the developing CNS resulted in a more 
severe phenotype compared to loss of each gene alone, revealing that these 
proteins are not functionally redundant (82). Interestingly, Mdm2 overexpression can 
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compensate for Mdm4 deficiency and rescue the embryonic lethal phenotype by 
dampening p53 activity (83).  
In addition, while Mdm2+/− or Mdm4+/− mice have a normal life span, both are 
radiosensitive and, upon DNA damage, succumb to p53-dependent early death (43). 
On the other hand, Mdm2+/− Mdm4+/− double-heterozygous mice are not viable due to 
neural and hematopoietic defects. This phenotype is rescued by loss of a single p53 
allele, underscoring the fine-tuning in the p53/Mdm2/Mdm4 regulatory network and 
the cell-type specific sensitivity (43). Moreover, conditional deletion of Mdm2 in adult 
mice is also lethal due to extensive p53-induced irreversible tissue damage (34, 84), 
whereas deletion of Mdm4 under similar condition is compatible with life (85). 
 
b. p53-independent functions of Mdm4 
Although the main known function of Mdm4 is inhibition of p53 activity, Mdm4 
was found to have p53-independent roles. Mdm4−/− p53−/− double null mice have 
shorter survival compared to p53−/− mice and chromosomal studies on derived tumor 
cells as well as MEFs reveal that Mdm4 indeed suppresses multipolar mitotic spindle 
formation and chromosome loss independent of p53 and Mdm2 (86). Additionally, 
elevated levels of Mdm4 delay DNA damage response and enhance genome 
instability and transformation. These functions are also independent of p53 and 
Mdm2 (87). Combined, these studies underscore the importance of Mdm4 levels per 
se in maintaining genomic stability. 
Additionally, Mdm4 interacts with p21, promotes its proteasomal degradation 
in an ubiquitin-independent process and, consequently, abrogates G1 cell-cycle 
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arrest. p21 degradation by Mdm4 is independent of, but cooperates with Mdm2 (88). 
E2F-1 is another protein that Mdm4 binds to and represses its transactivation 
independent of Mdm2 and p53. Unlike the p21-Mdm4 interaction, Mdm4 does not 
alter E2F-1 protein level, but reduces its ability to bind to its consensus DNA 
sequence (89) or increases cytoplasmic localization of E2F-1 (90).  
 
Role of Mdm4 in tumorigenesis and lessons from animal models 
Many human tumors have high level of MDM4 due to either gene 
amplification or overexpression. For instance, elevated levels of MDM4 are detected 
in retinoblastoma (91, 92), melanoma (93), colon cancer (58, 94), breast cancer (94, 
95), Ewing sarcoma (96), lung cancer (94), prostate cancer (97), glioblastoma (98) 
and hematopoietic neoplasms such as pre-B acute lymphoblastic leukemia (ALL) in 
adults (99) and acute myeloid leukemia (AML) (100).  
Given that many tumors have high levels of MDM4 and that MDM4 is a critical 
regulator of p53, it was postulated that MDM4 overexpression in vivo would be 
tumorigenic. In fact, three independent lines of Mdm4 transgenic mice develop 
spontaneous tumors in which the Mdm4 transgene is driven by the cytomegalovirus 
(CMV) immediate-early (IE) enhancer and the chicken β-actin promoter, allowing 
ubiquitous expression of Mdm4 (41). In addition, this Mdm4 transgenic mouse in the 
background of p53 heterozygosity also accelerates tumorigenesis and shows a 
distinct tumor spectrum from mice with either genetic change alone, highlighting the 
cooperation of Mdm4 and p53 during tumor development (41).  
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The Mdm4-p53 axis, a targetable pathway for cancer therapy 
The major role of MDM4 in tumor development and progression is to inhibit 
p53 transcriptional activity. Interestingly, a large number of the tumors with high 
MDM4 retain wild type p53. Mdm4 exerts its inhibitory effect via physical masking of 
the transactivation domain of p53 and unlike Mdm2, has no role in controlling the 
level of p53 protein by degradation. Accordingly, mouse studies showed that 
deletion of Mdm2 in adult mice causes detrimental p53-mediated tissue damage and 
death (34, 84), whereas deletion of Mdm4 under comparable conditions only results 
in minor reversible damages (85).  Thus disruption of the Mdm4-p53 interaction and 
restoration of wild type 53 activity has been proposed as a druggable target and 
tested as an anti-cancer therapy in mouse models. Interestingly, using Nutlin-3, a 
small molecule inhibiting the p53-Mdm2 interaction as well as the p53-Mdm4 
interaction with lower affinity, combined with Topotecan in retinoblastoma xenograft 
model (91) enhances sensitivity to cytotoxic agents and synergistically kills tumor 
cells. Moreover, SAH-p53-8, a stapled peptide interrupting the MDM-p53 interaction, 
combined with Cisplatin in melanoma cell lines also results in higher tumor cell death 
compared to treatment with chemotherapeutic agent alone (93). Such data 
encourage combination therapy and adding Mdm4 inhibitors to the therapeutic 
regimen of tumors with high expression of Mdm4 and wild type p53.  
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p73, the guardian’s elder brother 
 
 p73 was discovered approximately 2 decades after p53 and named “the long 
lost cousin of p53” due to its substantial degree of structural and functional 
homology to p53. Since then, various in-depth and detailed studies have shown that 
despite the similarities, p73 has differences in structure as well as function. The 
structural analyses suggest that p73 is the ancestor of p53 and, for this reason it is 
also called “the guardian’s elder brother” (101). Moreover, the functional studies 
showed that this gene has remarkable roles during development.  
 
p73 Structure 
The human p73 gene maps to chromosome 1p36.3, a region frequently 
deleted in a subset of human cancers. It has 14 exons with the first coding sequence 
in exon 2. Compared to p53, p73 has larger introns and a few more exons. The 
larger size of introns permits a higher level of recombination and greater diversity of 
haplotypes. 
p73 has high structural homology to p53. Similar to p53, p73 has an N-
terminal TAD with 30% homology to p53, a DBD with the highest sequence similarity 
to p53 (63%) (2) and an OD with 38% identity (2, 102) (Figure 4). Having the highest 
homology in the DBD as well as identical residues that interact with DNA, allows p73 
to bind to the consensus p53-binding site, activate common target genes and 
mediate apoptosis and cell cycle arrest (103). On the other hand, p73 and p53 have 
the most prominent structural differences in the C-terminus. While p53 has 
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approximately 30 amino acids at the C-terminus that interact with DNA 
nonspecifically, p73 has more than 200 amino acids, which includes a sterile-alpha 
motif (SAM) domain (a protein-protein domain) (104).  Most proteins with SAM 
domains have a regulatory role during development (105); this supports the notion 
that p73 is involved in differentiation and development. 
 Shortly after its identification, the p73 gene was characterized to have a dual 
structure with a distal and internal promoter in intron-3 as well as at least seven 
alternatively spliced C-terminal isoforms (α, β, γ, δ, ε, ζ, η). At that time, only one full-
length isoform was known for p53, a notion that changed thereafter (106, 107). The 
distal promoter leads to the expression of a full-length TAp73 isoform with 
transactivation activity, whereas the internal promoter leads to expression of the 
∆Np73 isoform, an N-terminally truncated protein lacking the transactivation domain 
(107) (Figure 4).  
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Figure 4. Schematic representation of p73 structure and comparison of domain 
structure of p53 and p73. p53 and p73 share similarity in TAD, DBD and OD. The 
percentage identity shared between these domains is indicated. p73 has two main 
isoforms: The TAp73 isoform, a full-length protein with TAD at N-terminus, and the 
ΔNp73 isoform, an N-terminally truncated protein lacking TAD. P73 also has 
alternatively spliced C-terminal isoforms such as α, β and γ. All these isoforms have 
the DNA binding domain (DBD) and the oligomerization domain (OD), and some 
such as TAp73α and ΔNp73α have extra domains, for instance sterile-alpha motif 
(SAM) domain.  
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p73 regulators 
Similar to p53, the stability and activity of p73 are regulated through protein-
protein interactions and subsequently post-translational modifications, such as 
ubiquitination, phosphorylation and acetylation (108, 109). 
In response to genotoxic stress, one of the first modifications of p73 is 
phosphorylation by a non-receptor tyrosine kinase, c-Abl, at Tyr99, Tyr121 and 
Tyr240 (110), which leads to p73 interaction with other proteins such as PIN1, and 
acetylation by p300 and eventually its stabilization and activation (111, 112). 
Moreover, c-Abl activates JNK/p38 MAPK pathway, which in turn phosphorylates 
p73 at threonine residues close to proline and promotes its accumulation (113). c-
Abl also phosphorylates YAP, which further associates with p73 and promotes p73 
transcriptional activity (114).  
p73 is also phosphorylated during cell cycle by cyclin-dependent kinases 
(CDKs) in unstressed cells.  Phosphorylation of p73 at threonine 86 in the by S/G2/M 
CDK complexes decreases p73 transcriptional activity and enables cell cycle 
progression (115).  
Similar to p53, the level of p73 is mainly regulated by the ubiquitin-
proteasome system. Itch, a HECT-domain E3 ubiquitin ligase, was the first enzyme 
identified to target p73 for proteasomal degradation (116). Two proteins, N4BP1 and 
YAP, modulate this process by competing with Itch in their binding to p73 (117, 118). 
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p73 functions  
Given that p73 has various isoforms with distinct functions, the overall activity 
of p73 depends on the ratio of its different isoforms.    
a. Tumor suppressor activity of TAp73 
1. Growth arrest  
The TAp73 isoform, which contains the N-terminal TAD, suppresses 
tumorigenesis by mediating cell cycle arrest and apoptosis as well as maintaining 
genome stability. Similar to p53, TAp73 activates p21, GADD45 and 14-3-3σ to 
induce cell cycle arrest in G1 and G2/M (119-123). Furthermore, it regulates the 
number of cell divisions by repressing human telomerase reverse transcriptase 
(hTERT) expression. However, the mechanism is controversial: some studies 
suggest this is through Sp1, whereas others propose it is through NF-YB2 (124, 
125). 
2. Genomic stability 
 p73 inhibits polyploidy and aneuploidy through regulation of G2-M damage 
checkpoints in a p53-independent manner (126). Moreover, upon DNA double-
strand breaks, p73 regulates DNA repair through upregulation of Brca2 and Rad51, 
genes involved in homologous recombination (HR) DNA repair pathway (127). More 
detailed studies on isoforms revealed that TAp73-deficient MEFs and oocytes have 
mitotic spindle defects and premature mitotic exits (128). Further studies showed 
that the interaction of TAp73 with BubR1 in the spindle assembly checkpoint (SAC) 
complex is essential for proper mitosis and lack of this isoform leads to dysfunctional 
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SAC and consequently aberrant mitosis and aneuploidy (129).  Moreover, p73 
coordinates mitotic exit via p57 transactivation (130) and mediates mitotic cell death 
through Bim upregulation (131).  
3. Apoptosis  
 Upon stress, TAp73 induces cell death though various pathways. It regulates 
mitochondrial-mediated apoptosis through transactivation of p53 target genes such 
as Bcl-2 family members Bax, Puma and Noxa or via activation of Gramd4 in a p53-
independent manner (132-134). p73 also plays a role in the extrinsic apoptosis 
pathway by stimulating expression of CD95, TNF-R1, TRAIL-R1 and TRAIL-R2 
(134, 135). Moreover, TAp73 induces endoplasmic reticulum stress by upregulating 
Scotin in response to DNA damage (134). 
 
b. Oncogenic activity of ∆Np73 
Since ∆Np73 does not have the TA domain, it is unable to induce gene 
expression and consequently does not mediate growth arrest or cell death. 
However, this isoform impacts these functions by its dominant-negative effect on 
TAp73 and p53. ∆Np73 isoforms oligomerize with TAp73 isoforms or compete with 
p53 on binding to p53 target genes to compromise their transcriptional function. 
Intriguingly, both TAp73 and p53 induce the expression of ∆Np73, forming a 
feedback loop to fine-tune the tumor suppressor activity of TAp73 and p53 (136, 
137). Therefore, the ratio and activity of TAp73 and ∆Np73 isoforms determine the 
cell fate. Shifting the balance towards ∆Np73 favors cancer progression by inhibiting 
the growth arrest and death of tumor cells as well as enhancing the tumorigenic 
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phenotype by ∆Np73 gain of function properties, such as chemoresistance, 
induction of EMT and metastasis (109, 136, 138). 
 
Role of p73 during development and lessons from animal models 
One distinct difference between p53 and p73 is their role during development. 
While p53-null mice are for the most part viable without prominent developmental 
defects, p73-deficient mice have multiple developmental abnormalities. These mice 
are runted with a high mortality rate (139). However, the severity depends on the 
background of mice. More than 75% of p73−/− mice in the SJ129 background die in 
less than a month, whereas p73−/− mice in a mixed genetic background survive 
longer (107). The cause of the early death is usually gastrointestinal hemorrhage or, 
less commonly, intracranial bleeding (139).  
Surviving p73−/− mice acquire generalized pan-mucositis and chronic bacterial 
infections, which are characterized by massive inflammation and neutrophil 
aggregation. However, no obvious deficiencies were identified in lymphoid or 
granulocyte populations, indicating that the phenotype is mainly related to the 
surface barriers of innate immune system such as epithelial lining of the mucosa and 
secreted mucosa and cytokines (2, 139). Moreover, p73 deficiency causes 
abnormalities in pheromonal signaling pathways, which results in lack of sexual 
interest and infertility in mature p73−/− mice (139). In addition, p73−/− mice display 
severe neurological defects including the core triad of p73 deficiency in the brain: 
cortical hypoplasia, hippocampal malformation and ventriculomegaly (139, 140). 
This phenotype varies in severity: the severe form has massive apoptosis and 
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causes early postnatal death, whereas the mild form has none or low levels of 
apoptosis and half of the pups might survive to adulthood (140).  
p73 has a role in corticogenesis as early as E12.5, as evidenced by ectopic 
neurons in p73-deficient preplate and cortical hem (141), and the decrease in 
cortical thickness becomes apparent after E14.5, ranging from 10-30% compared to 
wild type brain at the same developmental stage. It seems that hypoplasia of the 
cortical plate is due to defect in neural stem cells (140). At this stage, the size of 
ventricles is normal. However, ventriculomegaly and subsequently hydrocephalus 
happen shortly after birth and the severity is also variable. Hydrocephalus is a 
communicating form, indicating a defect in production or reabsorption of cerebral 
spinal fluid (CSF) due to loss of p73 in ependymal cells (139, 140). In addition, the 
p73−/− hippocampus has 3 characteristics: absence of Cajal-Retzius (CR) cells, lack 
of hippocampal fissures and dysgenesis of dentate gyrus (2, 139, 141). CR cells are 
early born neurons in the marginal zone of the developing cortex. These cells 
secrete Reelin, which is essential for radial migration of neurons (141, 142). 
Absence of these cells in p73−/− mice causes architectonic abnormalities in the 
hippocampus, characterized by unusual arrangement of the CA1-CA3 pyramidal cell 
layer and lack of inferior blade of dentate gyrus (139, 141). Moreover, absence of 
hippocampal fissure indicates the significance of p73 in cortical folding (141).  
 A more detailed characterization of the phenotype of p73-deficient mice was 
learned from genetic studies on two p73 major isoforms, TAp73 and ∆Np73. Like 
p73−/− mice, TAp73−/− female and male mice are infertile due to abnormal mating 
behavior. Additionally, TAp73−/− female mice ovulate fewer oocytes compared to wild 
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type females and among those ovulated ones, some are retained under the bursa of 
ovary (128). Moreover, TAp73−/− male mice show increased DNA damage and cell 
death in spermatogonia as well as defective spermatids, which result in hypospermia 
and infertility (143). On the contrary, loss of ∆Np73 does not interfere with fertility 
(144). Moreover, the only neurological defect of TAp73−/− mice is hippocampal defect 
comparable to p73−/− hippocampal abnormality (128), while ∆Np73−/− mice have 
reduced cortical thickness and decreased neuronal density in old age, compatible 
with neurodegeneration, compared to wild type mice at the same age (144). Such 
neuroanatomical alterations along with behavioral changes suggestive of 
Alzheimer’s disease has been reported in the aged p73+/− mice (145).  
 
Role of p73 in tumorigenesis and lessons from animal models 
Unlike p53, p73 is mutated in less than 0.5% of human tumors (136). 
However, several studies have shown that p73 is altered in various tumor types 
through loss of heterozygosity (LOH) or epigenetic silencing, including different 
types of lymphoma and leukemia (146-149), glioma (150), neuroblastoma (151), 
ovarian cancer (152), breast cancer (153) and colorectal cancer (154). Such 
observations emphasize p73 tumor suppressor activity.  
In fact, genetic studies clearly highlight this function as p73+/− mice have 
significantly shorter life span compared to wild type mice and develop spontaneous 
thymic lymphoma, lung adenocarcinoma and hemangiosarcoma (155). Moreover, 
the combination of p73 loss with loss of other tumor suppressor genes such as p53 
or the presence of an oncogene such as Myc enhance tumor burden and/or increase 
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tumor dissemination or metastasis (155-157). To elaborate in more detail, the 
median age of p53+/− p73+/− mice is 6 months compared to 10 months in p53+/− mice. 
Furthermore, p53+/− p73+/− mice have 50% frequency of metastasis compared to 0- 
5% in p53+/− mice (155, 158, 159). Loss of one allele of p73 in the p53 null 
background does not have a significant effect on the survival, whereas p53−/− p73−/− 
mice have 11.5 days shorter life span compared to p53−/− mice. However, both 
p53−/− p73+/− and p53−/− p73−/− mice have higher rates of T-cell lymphoma (82% and 
83%, respectively) compared to p53−/− mice (66%). More importantly, more than 
75% of lymphomas in p53−/− p73+/− and p53−/− p73−/− mice are moderately to severely 
disseminated; whereas, only 10% of p53−/−  of lymphomas are moderately infiltrated 
to other organs (156). In Eµ-myc transgenic mice overexpressing Myc in B cells, loss 
of p73 does not affect survival; however, it strikingly promotes the dissemination of 
lymphoma. The p73−/− Eµ-myc mice have massive infiltration of lymphoma to lung, 
meninges, brain parenchyma and paravertebral ridges compared to Eµ-myc mice 
with localized lymphoma in lymph nodes and spleen (157).   
TAp73−/− mice have a shorter life span compared to wild type mice and 
approximately 70% of TAp73−/− and 30% of TAp73+/− mice in a mixed background 
succumb to tumorigenesis with lung adenocarcinomas and lymphomas being the 
most prevalent cancers, respectively (128). On the other hand, ∆Np73−/− mice have 
a normal life span and E1A/RasV12 transformed ∆Np73−/− MEFs develop significantly 
smaller tumors compared to wild type MEFs, underscoring that ∆Np73 deficiency 
impairs tumor formation in vivo (144). Collectively, the genetic in vivo studies support 
the notion that the TAp73 isoform functions as a tumor suppressor inducing cell 
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cycle arrest and apoptosis while the ∆Np73 isoform inhibits such transactivation 
activity in a dominant-negative manner (137, 160, 161). 
 
Interaction of Mdm4 with p73  
Given the significance of Mdm2 and Mdm4 in regulating p53 stability and 
activity in vivo and the high structural homology of p53 and p73 in the TA domain, 
several studies examined the interaction of Mdm proteins with p73. Interestingly, the 
co-expression of Mdm2 and p73 human embryonic kidney (HEK-293) cells with wild 
type p53 as well as p53-deficient human osteosarcoma (Saos-2) and lung 
adenocarcinoma (H1299) cells showed that similar to the p53-Mdm2 interaction, p73 
and Mdm2 bind via their N-termini (162-164). These in vitro studies revealed that 
such binding reduces p73 transcriptional activity (163, 165) and in turn p73-induced 
apoptosis (162). However, p53 and p73 bind to separate regions on Mdm2 (165) 
and, unlike p53, p73 is not destabilized or degraded by Mdm2 (162, 163). Moreover, 
recently, an in vivo study proposed that Mdm2 exerts its oncogenic activity through 
inhibiting both p53 and p73 functions (166).  
Mdm4, like Mdm2, can also bind to p73 (164); yet, whether such interaction 
represses p73 transcriptional activity remains to be elucidated. Interestingly, a 
detailed quantitative characterization of interaction of Mdm proteins with p53-family 
proteins has revealed that Mdm4 has higher affinity for p73 than p53 (167). To 
interrogate the biological significance of the Mdm4-p73 interaction in vivo, here, I 
present a comprehensive genetic characterization of the potential Mdm4 and p73 
interaction during both development and tumorigenesis. 
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CHAPTER 2. RESULTS 
 
Loss of p73 does not rescue the Mdm4-null embryonic lethality  
Mdm4-deficient mice die at E7.5 due to unrestricted p53 activity. This 
embryonic lethality is rescued by loss of p53. Since in vitro studies showed that 
Mdm4 interacts with p73, and, more interestingly, Mdm4 binds to p73 with higher 
affinity compared to p53, I asked whether the phenotype of Mdm4 deficiency is 
rescued by p73 loss and examined the phenotype of Mdm4∆2/∆2 p73−/− mice. I first 
crossed p73+/− mice with Mdm4+/∆2 mice to generate breeders with desirable 
genotype, Mdm4+/∆2 p73+/− mice. Next, I intercrossed Mdm4+/∆2 p73+/− mice to obtain 
Mdm4∆2/∆2 p73−/− embryos with the expected frequency of 6.25% or 1 in 16 mice.  
Mdm4∆2 allele is the null allele of Mdm4 which is generated by deletion of 
exon 2, the first coding exon, and no Mdm4 protein was detected by western blot in 
Mdm4∆2/∆2 p53−/− mouse embryonic fibroblasts (MEFs) (80). The p73 null allele is 
generated by the replacement of exon 5 and 6 with neomycin-resistant (NeoR) gene, 
and it does not have transcriptional activity due to the disruption of DNA-binding 
domain (139). Mdm4 is on mouse chromosome 1 and p73 is on chromosome 4, so 
these crosses were feasible. To overcome the issue of p73−/− infertility, I used p73 
heterozygous mice as breeders in each cross.  
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Rescue study at E11.5 
I intercrossed Mdm4+/∆2 p73+/− mice and first examined the rescue at mid-
gestation. At E11.5, I sacrificed pregnant females and collected 36 embryos with 
normal morphology, 2 resorbed embryos and 16 empty deciduae. I did not obtain 
any Mdm4∆2/∆2 p73−/− embryo with normal morphology; however, one of the two 
resorbed embryos was Mdm4∆2/∆2 p73−/− and the other was Mdm4∆2/∆2 (Table 1). The 
phenotypes of both were comparable, indicating that p73 loss does not rescue 
Mdm4∆2/∆2 phenotype at this developmental stage.  
 
Rescue study at E9.5 
Further, I studied the rescue at an earlier time point. I sacrificed pregnant 
females at E9.5 and obtained 37 embryos with normal morphology as well as 5 
resorbed embryos. The normal embryos were wild type or heterozygous for Mdm4, 
whereas the resorbed embryos were Mdm4-null with various p73 alleles (one 
Mdm4∆2/∆2 (1), Mdm4∆2/∆2 p73+/− (1) and Mdm4∆2/∆2 p73−/−  (3) embryos) (Table 2). 
Additionally, I observed no significant difference in the morphology of Mdm4∆2/∆2 
p73−/− compared to Mdm4∆2/∆2.  
 
Combined, all the Mdm4∆2/∆2 embryos, regardless of p73 genotype, were 
remnants of resorbed embryo with no recognizable morphology (Table 3) (χ2= 
30.000, df= 5, p-value < 0.0001), indicating that loss of p73, in the presence of 
unrestricted p53 activity, does not rescue the Mdm4-null phenotype. 
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Table 1. p73 loss does not rescue the Mdm4-null embryonic lethality at E11.5 
 
Cross: Mdm4+/∆2 p73+/−  ×  Mdm4+/∆2 p73+/− 
 
Number of embryos Percentage of embryos  
Genotype Observed Expected Observed Expected 
Mdm4+/+ p73+/+ 1 2.25 2.8 6.25 
Mdm4+/+ p73+/− 7 4.5 19.4 12.5 
Mdm4+/+ p73−/− 0 2.25 0 6.25 
Mdm4+/Δ2 p73+/+ 4 4.5 11.1 12.5 
Mdm4+/Δ2 p73+/− 14 9 38.9 25 
Mdm4+/Δ2 p73−/− 10 4.5 27.8 12.5 
Mdm4Δ2/Δ2 p73+/+ 0  2.25 0 6.25 
Mdm4Δ2/Δ2 p73+/− 0 4.5 0 12.5 
Mdm4Δ2/Δ2 p73−/− 0  2.25 0 6.25 
Total 36 ¶ 36 100 100 
 
Mdm4∆2/∆2 embryos are arrested at pre-gastrulation at E7.5. In total, one Mdm4Δ2/Δ2 
p73+/+ and one Mdm4Δ2/Δ2 p73−/−  remnants of resorbed embryos were collected at 
E11.5.    
¶
 Sixteen empty deciduae were also collected. 
Page | 34  
 
 
Table 2. p73 loss does not rescue the Mdm4-null embryonic lethality at E9.5 
 
Cross: Mdm4+/∆2 p73+/−  ×  Mdm4+/∆2 p73+/− 
 
Number of embryos Percentage of embryos  
Genotype Observed Expected Observed Expected 
Mdm4+/+ p73+/+ 0 2.3125 0 6.25 
Mdm4+/+ p73+/− 4 4.625 10.81 12.5 
Mdm4+/+ p73−/− 7 2.3125 18.92 6.25 
Mdm4+/Δ2 p73+/+ 2 4.625 5.4 12.5 
Mdm4+/Δ2 p73+/− 18 9.25 48.65 25 
Mdm4+/Δ2 p73−/− 6 4.625 16.22 12.5 
Mdm4Δ2/Δ2 p73+/+ 0  2.3125 0 6.25 
Mdm4Δ2/Δ2 p73+/− 0  4.625 0 12.5 
Mdm4Δ2/Δ2 p73−/− 0  2.3125 0 6.25 
Total 37 37 100 100 
 
Mdm4∆2/∆2 embryos are arrested at pre-gastrulation at E7.5. In total, one Mdm4Δ2/Δ2 
p73+/+, one Mdm4Δ2/Δ2 p73+/−  and three Mdm4Δ2/Δ2 p73−/−  remnants of resorbed 
embryos were collected at E9.5.    
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Table 3. p73 loss does not rescue the Mdm4-null embryonic lethality  
 
Cross: Mdm4+/∆2 p73+/−  ×  Mdm4+/∆2 p73+/− 
 
Number of embryos Percentage of embryos  
Genotype Observed Expected Observed Expected 
Mdm4+/+ p73+/+ 1 4.5625 1.369 6.25 
Mdm4+/+ p73+/− 11 9.125 15.068 12.5 
Mdm4+/+ p73−/− 7 4.5625 9.59 6.25 
Mdm4+/Δ2 p73+/+ 6 9.125 8.219 12.5 
Mdm4+/Δ2 p73+/− 32 18.25 48.836 25 
Mdm4+/Δ2 p73−/− 16 9.125 21.918 12.5 
Mdm4Δ2/Δ2 p73+/+ 0  4.5625 0 6.25 
Mdm4Δ2/Δ2 p73+/− 0  9.125 0 12.5 
Mdm4Δ2/Δ2 p73−/− 0  4.5625 0 6.25 
Total 73 73 100 100 
 
Mdm4∆2/∆2 embryos are arrested at pre-gastrulation at E7.5. In total, two Mdm4Δ2/Δ2 
p73+/+, one Mdm4Δ2/Δ2 p73+/−  and four Mdm4Δ2/Δ2 p73−/−  remnants of resorbed 
embryos were collected at E11.5 and E9.5.   
¶
 Sixteen empty deciduae were also collected. 
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 Gene dosage study to determine if p53 haploinsufficiency contributes to the 
rescue of the Mdm4∆2/∆2 p73−/− phenotype  
I further examined the contribution of both p53 and p73 to the rescue of 
Mdm4∆2/∆2 early embryonic lethality. I set up crosses to determine whether the 
Mdm4∆2/∆2 p53+/− p73+/− or Mdm4∆2/∆2 p53+/− p73−/−  mice are viable or 
developmentally more advanced compared to Mdm4∆2/∆2 p53+/− embryos.  
Since p53 is on mouse chromosome 11, it was possible to generate triple 
heterozygous Mdm4+/∆2 p53+/− p73+/− mice. I then intercrossed Mdm4+/∆2 p53+/− p73+/− 
mice to generate the breeders with desirable genotypes, Mdm4∆2/∆2 p53−/− 
p73+/−  and Mdm4∆2/∆2 p53−/− mice. 
 
Gene dosage study at P7 
I then crossed Mdm4∆2/∆2 p53−/− p73+/− with Mdm4+/∆2 p73+/− mice to obtain 
Mdm4∆2/∆2 p53+/− p73+/− or Mdm4∆2/∆2 p53+/− p73−/−  mice with the expected probability 
of 25% (1 out of 4 mice) and 12.5% (1 out of 8 mice), respectively. I analyzed 27 
pups at postnatal day 7 (P7) and I found that neither Mdm4∆2/∆2 p53+/− p73+/− nor 
Mdm4∆2/∆2 p53+/− p73−/− pups are born alive (Table 4) (χ2=27.667, df =5, p-value< 
0.0001). I therefore performed a developmental study for possible rescue. 
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Table 4. p73 is haploinsufficient to rescue the Mdm4∆2/∆2 p53+/− phenotype at P7 
 
Cross: Mdm4∆2/∆2 p53−/− p73+/−  ×  Mdm4+/∆2 p73+/− 
 
Number of pups Percentage of pups  
Genotype Observed Expected Observed Expected 
Mdm4+/Δ2 p53+/− p73+/+ 6 3.375 22.22 12.5 
Mdm4+/Δ2 p53+/− p73+/− 13 6.75 48.15 25 
Mdm4+/Δ2 p53+/− p73−/− 8 3.375 29.62 12.5 
Mdm4Δ2/Δ2 p53+/− p73+/+ 0  3.375 0 12.5 
Mdm4Δ2/Δ2 p53+/− p73+/− 0  6.75 0 25 
Mdm4Δ2/Δ2 p53+/− p73−/− 0  3.375 0 12.5 
Total 27 27 100 100 
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Gene dosage study at E11.5 
Given that Mdm4∆2/∆2 p53+/− mice are not viable (79), I further examined the 
role of p53 gene dosage in the rescue of Mdm4∆2/∆2 early embryonic lethality and  
the effect of p73 loss on the phenotype of Mdm4∆2/∆2 p53+/− embryos. I crossed 
Mdm4∆2/∆2 p53−/− with Mdm4+/∆2 p73+/− mice to test whether 50% reduction in p53 
gene dosage extends the lifespan of Mdm4∆2/∆2 embryos and concomitantly whether 
deletion of one allele of p73 suffices to further advance the partial rescue. At E11.5, I 
observed 10 Mdm4+/∆2 p53+/− embryos with normal morphology as well as 17 
Mdm4∆2/∆2 p53+/− embryos with an aberrant developmental phenotype, suggesting 
that deletion of one allele of p53 cannot completely rescue the Mdm4∆2/∆2 phenotype. 
However, decreased p53 dosage in Mdm4∆2/∆2 p53+/− embryos did lead to a partial 
rescue of Mdm4-null embryonic lethal phenotype. Although these embryos were still 
severely runted compared to Mdm4+/∆2 p53+/− embryos (Figure 5a-c), they overcame 
pre-gastrulation arrest and developed further, as evidenced by the formation of a 
neural groove with neural folds on each side as well as the allantois, a conspicuous 
landmark of gastrulation (168). The observation of partial rescue due to haploid loss 
of p53 is in agreement with findings from another Mdm4 knockout mouse model, 
which is lethal at later developmental stage (E10.5) (169). Moreover, Mdm4∆2/∆2 
p53+/− and Mdm4∆2/∆2 p53+/− p73+/− embryos had comparable phenotypes, indicating 
that loss of one allele of p73 is not sufficient to rescue Mdm4∆2/∆2 p53+/− phenotype 
(Table 5) (χ2= 10.000, df= 3; p-value= 0.0186). 
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Table 5. Loss of one allele of p73 does not rescue the Mdm4∆2/∆2 p53+/− phenotype at 
E11.5 
 
Cross: Mdm4∆2/∆2 p53−/−   ×  Mdm4+/∆2 p73+/− 
 
Number of embryos Percentage of embryos  
Genotype Observed Expected Observed Expected 
Mdm4+/Δ2 p53+/− p73+/+ 5 2.25 50 25 
Mdm4+/Δ2 p53+/− p73+/− 5 2.25 50 25 
Mdm4Δ2/Δ2 p53+/− p73+/+ 0 §  2.25 0 25 
Mdm4Δ2/Δ2 p53+/− p73+/− 0 §  2.25 0 25 
Total 10 ¶ 10 100 100 
 
§At E11.5, nine Mdm4Δ2/Δ2 p53+/− p73+/+ and 8 Mdm4Δ2/Δ2 p53+/− p73+/− runted embryos 
were observed. All Mdm4Δ2/Δ2 p53+/− embryos, regardless of p73 genotype, were 
comparable morphologically. 
¶ Eight empty decidua were also collected. 
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Figure 5. Representative pictures of the gross morphology of Mdm4Δ2/Δ2 p53 
embryos at E11.5. (a) Mdm4+/Δ2 p53 embryo, (b,c) Mdm4∆2/∆2 p53 : The 
arrowhead points to the neural fold and the arrow points to the allantois. This 
phenotype was consistent among all Mdm4Δ2/Δ2 p53 embryos, regardless of p73 
genotype. Capturing the picture of the remnant of resorbed Mdm4Δ2/Δ2 embryos was 
not possible due to technical issues.  Bar: 1 mm   
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Gene dosage study at E9.5 
To determine whether the complete loss of p73 can extend the survival of 
Mdm4∆2/∆2 p53+/− embryos, I crossed Mdm4∆2/∆2 p53−/− p73+/− with Mdm4+/∆2 
p73+/− mice and analyzed embryos at an even earlier time point. At E9.5, I obtained 
18 Mdm4+/∆2 p53+/−  embryos, which were morphologically comparable to wild type, 
and 28 Mdm4∆2/∆2 p53+/− embryos, which were were abnormally small (Table 6) (χ2= 
30.000, df= 5, p-value < 0.0001). The Mdm4∆2/∆2 p53+/− embryos in the background 
of wild type, heterozygous or null p73 allele had the same phenotype (Figure 6), 
suggesting that the unrestricted haploid level of p53 is strong enough to cause 
embryonic lethality. 
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Table 6. p73 loss does not prolong the partial rescue of Mdm4∆2/∆2 p53+/− embryos at 
E9.5 
 
Cross: Mdm4∆2/∆2 p53−/− p73+/−  ×  Mdm4+/∆2 p73+/− 
 
Number of embryos Percentage of embryos  
Genotype Observed Expected Observed Expected 
Mdm4+/Δ2 p53+/− p73+/+ 1 2.25 5.55 12.5 
Mdm4+/Δ2 p53+/− p73+/− 14 4.5 77.78 25 
Mdm4+/Δ2 p53+/− p73−/− 3 2.25 16.67 12.5 
Mdm4Δ2/Δ2 p53+/− p73+/+ 0 §  2.25 0 12.5 
Mdm4Δ2/Δ2 p53+/− p73+/− 0 § 4.5 0 25 
Mdm4Δ2/Δ2 p53+/− p73−/− 0 §  2.25 0 12.5 
Total 18 ¶ 27 100 100 
 
§
 At E9.5, seven Mdm4∆2/∆2 p53+/− p73+/+, 16 Mdm4∆2/∆2 p53+/− p73+/− and 5 Mdm4∆2/∆2 
p53+/− p73−/− developmentally retarded embryos were observed.  
¶ Six empty deciduae were also collected. 
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Figure 6. Representative pictures of the gross morphology of Mdm4Δ2/Δ2 p53 
embryos at E9.5. (a) Mdm4+/Δ2 p53, (b) Mdm4∆2/∆2 p53, (c) Mdm4∆2/∆2 p53 
p73 embryos. Capturing the pictures of the remnant of resorbed Mdm4Δ2/Δ2 and 
Mdm4∆2/∆2 p73 embryos were not possible due to technical issues. Bar: 1 mm   
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Loss of p73 does not rescue the Mdm4∆2/∆2 embryonic brain phenotype 
Next, I focused on the possible cooperation of Mdm4 and p73 during 
development of the brain, an organ wherein both Mdm4 and p73 have well-
established role during embryogenesis. Additionally, such organ-specific approach 
would circumvent widespread p53-mediated early embryonic lethality of Mdm4 
deficiency.  
Mdm4 plays an important role in neural development by regulating p53 (169). 
Conditional deletion of Mdm4 in the developing CNS by Nestin-driven Cre 
recombinase (Nes-cre) starting as early as E10.5 (82, 170) results in porencephaly, 
a cavity in the cerebrum, and pups are not viable after birth due to severe brain-
tissue deficiency. This phenotype is a gradually progressive neuronal loss due to 
both cell cycle arrest and apoptosis and completely rescued by deletion of p53 (82).  
On the other hand, p73 is well known as a multifunctional protein in the field 
of neurobiology (171) and crucial for maintenance of neural stem cells (172, 173). 
p73 is expressed sparsely in preplate, the first stage in corticogensis, as early as 
E10.5, and it is highly expressed throughout the cortical hem and in CR cells at 
E12.5 (139, 141). However, the phenotype of p73-deficiency in the brain is not 
evident during prenatal life, except mild cortical hypoplasia after E14.5. The core 
triad of neurological defects in p73−/− mice, including cortical hypoplasia, 
hippocampal dysgenesis and ventriculomegaly, is only prominent in postnatal and 
adult mice (140).  
Given that both Mdm4 and p73 has established roles in the development of 
embryonic brain, we tested whether Mdm4 is a negative regulator of p73 during CNS 
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development and examined if the phenotype of Mdm4 deficiency in the CNS is 
rescued by p73 loss. In this study, I used the Mdm4fx allele in which the floxed exon 
2 is deleted upon expression of Cre recombinase under control of Nestin promoter 
and neuron specific enhancer (82, 170). Such Cre-mediated recombination is highly 
efficient and specific (82).  
We crossed Mdm4fx/fx p73+/− mice with Mdm4+/fx p73+/− Nes-cre mice to 
generate Mdm4fx/fx p73−/− Nes-cre embryos. Embryos were collected at E14.5, the 
earliest time point that apoptosis and cell cycle arrest due to lack of Mdm4 are 
apparent in the embryonic brain (82). In total, 121 embryos were collected (Table 7). 
The first 48 embryos were fixed in 4% paraformaldehyde and among those, the ones 
with the following genotype were subjected to histopathological studies: Mdm4+/fx 
and Mdm4fx/fx (wild type embryonic brain), Mdm4+/fx p73−/− and Mdm4fx/fx p73−/− (p73−/− 
embryonic brain), Mdm4fx/fx Nes-cre (Mdm4∆2/∆2 embryonic brain), and Mdm4fx/fx 
p73−/− Nes-cre (Mdm4∆2/∆2 p73−/− embryonic brain). The midline sagittal sectioning 
revealed that the phenotype of porencephaly in all three Mdm4fx/fx Nes-cre embryos 
and seven Mdm4fx/fx p73−/− Nes-cre embryonic brains was comparable (Figure 7).  
Moreover, Mdm4fx/fx p73−/− Nes-cre brains, similar to Mdm4fx/fx Nes-cre, had 
decreased proliferation and increased apoptosis rates, as evidenced by Ki67 and 
cleaved caspase-3 (CC3) staining, and there was no difference in the pattern of 
proliferation and apoptosis between the two genotypes (Figure 8). These results 
clearly show that even in a tissue wherein p73 has prominent functions, disrupting 
the Mdm4-p73 interaction is not a major cause of the Mdm4-null phenotype. 
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Table 7. p73 loss does not rescue the Mmd4-deficiency brain phenotype 
 
 
Cross: Mdm4+/fx p73+/− Nes-cre  ×  Mdm4fx/fx p73+/− 
 
  
Number of embryos Percentage of embryos  
Genotype Observed Expected Observed Expected 
Mdm4+/fx p73+/+ 5 7.5625 4.1 6.25 
Mdm4+/fx p73+/+ Nes-cre 6 7.5625 5 6.25 
Mdm4+/fx p73+/− 9 15.125 7.4 12.5 
Mdm4+/fx p73+/− Nes-cre 18 15.125 14.9 12.5 
Mdm4+/fx p73−/− 8 7.5625 6.6 6.25 
Mdm4+/fx p73−/− Nes-cre 11 7.5625 9.1 6.25 
Mdm4fx/fx p73+/+ 10 7.5625 8.3 6.25 
Mdm4fx/fx p73+/+ Nes-cre 10§ 7.5625 8.3 6.25 
Mdm4fx/fx p73+/− 11 15.125 9.1 12.5 
Mdm4fx/fx p73+/− Nes-cre 15§ 15.125 10.7 12.5 
Mdm4fx/fx p73−/−  4 7.5625 3.3 6.25 
Mdm4fx/fx p73−/− Nes-cre 14§ 7.5625 13.2 6.25 
Total 121 121 100 100 
 
§All embryos displayed porencephaly. 
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Figure 7. Loss of p73 does not rescue the Mdm4-null porencephaly phenotype. 
Representative pictures of the sagittal sections of embryos at E14.5. The genotype 
of brain is mentioned on each column.  Sections are stained with H&E.  
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Figure 8. Loss of p73 does not affect the pattern of proliferation and apoptosis in the 
Mdm4-null brain phenotype. Representative sagittal sections of embryos at E14.5, 
the genotype of brain is mentioned in each column.  Sections are stained with H&E 
(a-c) or subjected to immunohistochemistry for Ki67 (d-f) as a marker of proliferation 
or cleaved caspase-3 (g-i) as a marker of apoptosis. The arrow points to positive 
Ki67 cells and the arrowhead points to positive CC3 cells. 
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Mdm4 inhibits the expression of some p73 and p53 target genes in the 
embryonic brain 
Given the strong evidence of the Mdm4-p73 interaction in vitro, we decided to 
interrogate the inhibitory regulation of Mdm4 on p73 activity at the molecular level in 
our system. Several studies have been performed to identify the p73 specific target 
genes in various cell types or cancer cell lines under different conditions. In each set 
of experiments, different target genes have been identified (121, 122, 127, 173).  
Thus, we decided to examine, in our experimental model system, genes identified as 
p73 targets and known to play a role in the developing CNS or adult brain. Since p53 
and p73 have the highest homology in their DNA binding domain compared to other 
domains (174), it is not surprising that a number of candidate genes are in fact 
common p53 and p73 target genes.  
Although the phenotype of Mdm4 deficiency was apparent at E14.5, there 
was sufficient brain tissue remaining for RNA isolation. Thus, 73 embryos were 
collected at this time point and their brains were dissected and preserved in TRIzol. 
The embryos with the following genotypes were used for RNA isolation and 
subsequently gene expression analysis by real-time RT-qPCR: Mdm4+/fx and 
Mdm4fx/fx (wild type embryonic brain), Mdm4+/fx p73−/− and Mdm4fx/fx p73−/− (p73−/− 
embryonic brain), Mdm4fx/fx Nes-cre (Mdm4∆2/∆2 embryonic brain), Mdm4fx/fx 
p73−/− Nes-cre (Mdm4∆2/∆2 p73−/− embryonic brain). The Mdm4∆2/∆2 p53−/− embryonic 
brains at E14.5 were obtained from intercrossing Mdm4∆2/∆2 p53−/− mice.  
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p53 and p73 common target genes 
14-3-3σ 
14-3-3σ is a p53 target gene, which inhibits G2/M progression and induces 
cell cycle arrest (175). Overexpression of p73 upregulates the transcript of 14-3-3σ 
two to six times higher than by does p53 overexpression (121, 122) and that p73 
directly binds to the consensus p53/p73-binding site in the regulatory region of 14-3-
3σ gene (121), suggesting that 14-3-3σ might be a bona fide target of p73.  
Interestingly, a comprehensive study on the differential expression of 14-3-3 protein 
isoforms showed that 14-3-3σ is located in the nuclei of developing rat hippocampus 
neurons (176) as well as human hippocampus (177), corresponding to the region 
that p73−/− and TAp73−/− mice display brain phenotypes.  
To examine the inhibitory effect of Mdm4 on p73 in the developing CNS, I 
asked whether deletion of Mdm4 in the embryonic brain upregulates 14-3-3σ 
transcript levels. As control, I used Mdm4∆2/∆2 p73−/− and Mdm4∆2/∆2 p53−/− embryonic 
brains. Indeed, 14-3-3σ was highly expressed in Mdm4∆2/∆2 embryonic brain 
compared to wild type (p-value < 0.01) and deletion of p73 or p53 abrogates such 
transcriptional upregulation (p-value < 0.01 and <0.05, respectively) (Figure 9), 
indicating that both p53 and p73 regulate 14-3-3σ. 
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Figure 9. Deletion of Mmd4 results in the upregulation of 14-3-3σ, a p73 and p53 
common target gene, in the embryonic brain. Real-time RT-qPCR was performed for 
14-3-3σ mRNAs in the wild type (n=7), p73-/- (n=7), Mdm4-/- (n=6), Mdm4-/- p73-/- 
(n=7) and Mdm4-/- p53-/- (n=4) embryonic brains at E14.5. ** p< 0.01, ns p >0.05  by 
ANOVA and Newman-Keuls multiple comparisons test. Error bars:SEM. 
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Perp 
Perp is another p53 target gene, which mediates apoptosis (178) in a cell 
context-dependent manner (179).  More specifically, studies on Perp-deficient mice 
have shown that Perp exerts its p53-dependent apoptosis in the developing CNS as 
well as thymocytes; however, it is dispensable for apoptosis in E1A-expressing 
MEFs (179). Four p53 binding sites have been recognized within the promoter and 
the first intron of the murine Perp gene (180) and it had been suggested that p73 
might bind to these sites as well (181).  
I therefore examined the effect of Mdm4 loss on Perp expression in the 
presence and absence of p53 or p73.  Perp was significantly upregulated in 
Mdm4∆2/∆2 embryonic brain compared to wild type brains (p-value < 0.01), while loss 
of either p53 or p73 abolished its expression (p-value < 0.01 and <0.05, 
respectively) (Figure 10).  
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Figure 10. Deletion of Mmd4 results in the upregulation of Perp, a p73 and p53 
common target gene, in embryonic brain. Real-time RT-qPCR was performed for 
Perp mRNAs in the wild type (n=7), p73-/- (n=7), Mdm4-/- (n=6), Mdm4-/- p73-/- (n=7) 
and Mdm4-/- p53-/- (n=4) embryonic brains at E14.5. ** p< 0.01, ns p >0.05  by 
ANOVA and Newman-Keuls multiple comparisons test. Error bars:SEM. 
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p21 
p21 is the well-characterized canonical transcriptional target of p53 (182, 183) 
and a major mediator of p53-dependant cell cycle arrest. It was also recognized as 
one of the first p73 target genes in the cells overexpressing wild type p73; yet, unlike 
p53, p73 does not induce p21 in response to DNA damage (174). Moreover, the 
level of p21 induced by p53 was three to six times higher than p73 (122).  
I also examined the level of p21 in my model system and observed that p21 
was only upregulated in Mdm4-deficient embryonic brain in a p53-dependent 
manner (p-value < 0.01) (Figure 11). 
 
p73 specific target genes 
I also examined a number of p73 specific target genes, which modulate 
neurogenesis, including p57 (184, 185), Jag1 (186), Jag2 (121, 173, 186), Hes5 
(172, 173) and Notch2 (173); however, I did not observe any statistically significant 
increase in expression of these targets as a result of Mdm4 loss (data not shown).  
Combined, these observations highlight the dominance of p53 activity, which 
results in extensive cell cycle arrest and apoptosis in Mdm4-deficient embryonic 
brain and compromises the other pathways in the developing CNS. 
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Figure 11. Deletion of Mmd4 results in the upregulation of p21 in the embryonic 
brain in a p53-dependent manner. Real-time RT-qPCR was performed for p21 
mRNAs in the wild type (n=7), p73-/- (n=7), Mdm4-/- (n=6), Mdm4-/- p73-/- (n=7) and 
Mdm4-/- p53-/- (n=4) embryonic brains at E14.5. *** p< 0.001  , ** p< 0.01, *p<0.05, ns 
p >0.05  by ANOVA and Newman-Keuls multiple comparisons test. Error bars:SEM. 
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The cooperation of the Mdm4 and p73 during tumorigensis 
Given that overexpression of Mdm4 and loss of p73 have been implicated in 
tumor development, I asked whether these two alterations cooperate during 
tumorigenesis. Mdm4Tg15 is one of three generated Mdm4 transgenic mouse lines in 
our lab, which develop spontaneous tumorigenesis (41). Mdm4Tg15 MEFs express at 
least five times higher levels of Mdm4 compared to wild type MEFs and have 
dampened p53 activity (Figure 12). I crossed Mdm4Tg15 with p73+/− mice and 
established a cohort of Mdm4Tg15 p73+/− (23 mice), Mdm4Tg15 (17 mice), p73+/− (13 
mice) and wild type (5 mice) mice in C57BL/6 background. Since I initially planned to 
include Mdm4Tg15 p73−/− and p73−/− mice to the cohort, I also crossed Mdm4Tg15 
p73+/− with p73+/− mice. However, no Mdm4Tg15 p73−/− mouse was viable after 
postnatal day 21 (P21) due to malnutrition and growth retardation. There is also a 
possibility that C57BL/6 background contributed to the early lethality of these pups. 
In the tumor study, all mice were sacrificed due to poor health conditions or upon 
reaching the two-year endpoint of this study.  
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Figure 12. Level of Mdm4 and p21 transcripts in MEFs. Real-time RT-qPCR was 
performed for Mdm4 and p21 mRNAs in the wild type (n=6), Mdm4Tg15 (n=4), 
Mdm4Tg15 p73+/− (n=4), Mdm4Tg15 p73−/− (n=1) MEFs. **** p< 0.0001  , ** p< 0.01, by 
ANOVA and Newman-Keuls multiple comparisons test. Error bars:SEM. 
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At two years, 18 of 23 (78.3%) Mdm4Tg15 p73+/− mice had been sacrificed, 
compared to 15 of 17 (88.2%) Mdm4Tg15 and 1 of 13 (7.7%) p73+/− mice. Both 
Mdm4Tg15 p73+/− and Mdm4Tg15 mice had significantly shorter life span compared to 
p73+/− and wild type littermates (p-value <0.0001) and their median survival was 593 
and 665 days, respectively. However, the difference between the survival of 
Mdm4Tg15 p73+/− and Mdm4Tg15 mice was not significant (Figure 13).  
I further examined the tumor frequency and spectrum of each group. 78.2% 
(18 of 23) of Mdm4Tg15 p73+/− and 82.3% (14 of 17) Mdm4Tg15 mice develop tumor by 
two years of age, compared to 23% (3 of 13) of p73+/− mice. Moreover, Mdm4Tg15 
p73+/− and Mdm4Tg15 mice had comparable tumor phenotypes, mainly B-cell 
lymphoma, histiocytic or dendritic cell sarcoma and brain tumors, whereas p73+/− 
mice developed B-cell lymphoma, histiocytic or dendritic cell sarcoma and 
angiosarcoma (Figure 14) (Table 8). All tumors were initially diagnosed 
morphologically and, in case of lymphoma or sarcoma, the diagnoses were further 
confirmed by immunohistochemistry studies for makers such as CD45R /B220, CD3 
and lysozyme. All lymphomas were strongly positive for surface marker CD45R 
/B220, implying that they were of B-cell origin (Figure 15). 
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Figure 13. Kaplan-Meier survival curves of Mdm4Tg15 p73+/−, Mdm4Tg15, p73+/− and 
wild type mice. The number of animals per genotype is indicated. 
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Figure 14. The tumor spectrum of Mdm4Tg15 p73+/−, Mdm4Tg15 and p73+/− mice. n is 
the total number of tumors. 
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Table 8. Spontaneous tumor spectrum of Mdm4Tg15 p73+/−, Mdm4Tg15 and p73+/− 
mice 
Genotype  
Tumor type Mdm4Tg15  p73+/− a 
(n=18)#  
Mdm4Tg15 b  
(n=14)#  
p73+/− c 
(n=3)#  
Lymphoma 5 (25 %)§ 1 (6.7 %) 1 (33.3 %) 
Sarcoma 11 (55 %)¶ 12 (80 %)* 1(33.3 %) 
Brain tumor  4 (20 %) 2 (13.3 %) 0 
      Unclassified large cell tumor 4 1 0 
      Choroid plexus tumor 0 1 0 
Angiosarcoma 0 0 1(33.3 %) 
Total number of tumors 20 15 3 
a
 Among 23 Mdm4Tg15 p73+/− mice, 18 mice were sacrificed due to moribund 
condition. Sixteen of them were diagnosed with tumor and 2 mice had two primary 
tumors. Among 5 mice sacrificed due to 2-year time point, two mice were diagnosed 
with tumor.   
b Among 17 Mdm4Tg15 mice, 15 mice were sacrificed due to moribund condition. 
Fourteen of them were diagnosed with tumor and one mouse had two primary 
tumors. Between 2 mice sacrificed due to 2-year time point, one mouse was 
diagnosed with tumor. 
c
 Among 13 p73+/− mice, one mouse was sacrificed due to moribund condition and 
diagnosed with tumor. Among 12 mice sacrificed due to 2-year time point, two mice 
were diagnosed with tumor. 
# n is the number of mice histopathologically diagnosed with tumor. 
§ 4 out of five mice had disseminated lymphoma (infiltration in more than one organ). 
Two mice including the one with localized lymphoma had multiple primary tumors. 
¶
 6 out of eleven Mdm4Tg15 p73+/− mice had sarcoma in more than one organ. 
* 10 out of twelve Mdm4 Tg15 mice had sarcoma in more than one organ. 
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Figure 15. Representative histopathological sections stained with H&E (a, d) and 
subjected to immunohistochemistry for B-cell marker (CD45R /B220) (b, e) and T-
cell marker (CD3) (c, f) of the spleen of an Mdm4Tg15 p73+/− mouse with B-cell 
lymphoma. Magnification, ×4 for a-c and ×40 for d-f.  
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Similar to other tumor suppressor genes, p73 undergoes LOH during tumorigensis. 
To determine whether the tumors from Mdm4Tg15 p73+/− mice lose the wild type 
allele, I extracted DNA from tumor tissue or nodules of lymphoma in the spleen or 
liver and analyzed by PCR. Interestingly, all the tumors from Mdm4Tg15 p73+/− mice 
retained the wild type p73 allele (Figure 16), whereas at least 40% of p73+/− tumors 
has been reported to undergo LOH (166), suggesting that overexpressed Mdm4 
might be inhibiting the p73 wild type allele in Mdm4Tg15 p73+/− tumors. 
Intriguingly, four Mdm4Tg15 p73+/− mice had unclassified large cell brain 
tumors compared to only one Mdm4Tg15 mouse (20% of Mdm4Tg15 p73+/− mice 
compared to 6.6% of Mdm4Tg15 mice). Given that a subset of brain tumors has 
amplification of Mdm4 and/or homozygous deletion of p73 (98) and that molecular 
findings in this study suggest the inhibitory effect of Mdm4 on p73 in mouse 
embryonic brain, the observation of higher number of unclassified large cell brain 
tumors in Mdm4Tg15 p73+/− mice compared to Mdm4Tg15 mice also supports a 
potential Mdm4-p73 cooperation. 
Moreover, five Mdm4Tg15 p73+/− mice had B-cell lymphoma compared to only 
one Mdm4Tg15 mouse (21.7% of Mdm4Tg15 p73+/− mice compared to 5.8% of 
Mdm4Tg15 mice), and each lymphoma was highly disseminated, had another primary 
tumor such as sarcoma, or had several disseminated foci of lymphoma in lymphoid 
and nonlymphoid organs as well as multiple primary tumors (Figure 17-20). On the 
other hand, lymphoma in the Mdm4Tg15 mouse was localized in only one lymphoid 
organ, the mesenteric lymph node. Since several studies have suggested a role of 
p73 in lymphomagenesis (146, 147, 157), increased lymphomagenesis in Mdm4Tg15 
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p73+/− mice indicates a possible cooperation between Mdm4 and p73. Yet, these 
differences were not statistically significant compared to Mdm4Tg15 mice, perhaps 
due to a small sample size. 
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Figure 16. Representative examples of LOH analysis at p73 loci by genomic PCR of 
tumor (T) and normal (N) tissues from Mdm4Tg15 p73+/− mice. All tumors retained wild 
type allele of p73. 
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Figure 17. A representative histopathological examination (H&E staining) of a 
Mdm4Tg15 p73+/− mouse with highly disseminated lymphoma and multiple primary 
tumors. Lymphoma is disseminated in spleen (a), liver (b), lung (c), serosa of 
duodenum (d), pancreas (f), paraspinal skeletal muscles (g), uterus (h) and lymph 
node (the architecture of lymph node is replaced by lymphoma cells) (i). The second 
primary tumor is sarcoma in colon (e). Magnification, ×4.  
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Figure 18. The incidence of dissemination of lymphoma in Mdm4Tg15 p73+/−, 
Mdm4Tg15 and p73+/− mice. n is the number of mice with lymphoma. 
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Figure 19. The pattern of dissemination of lymphoma to various organs and number 
of lymphoid and non-lymphoid organs infiltrated with lymphoma in Mdm4Tg15 p73+/−, 
Mdm4Tg15 and p73+/− mice. 
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Figure 20. The lymphoma severity index in Mdm4Tg15 p73+/− (n=5), Mdm4Tg15 (n=1) 
and p73+/− (n=1) mice. Each mouse with lymphoma is depicted by a dot. 
Lymphoma Dissemination Index: 0: No lymphoma, 1: Lymphoma in one or more LNs 
in one LN groups, thymus or spleen (lymphoid organs), 2: Lymphoma in 2 or more 
LN groups either above or below diaphragm, 3: Lymphoma in 2 or more LN groups 
above and below diaphragm, 4: Lymphoma in non-lymphoid tissues 
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CHAPTER 3. DISCUSSION AND FUTURE DIRECTIONS  
 
The observations that Mdm4 is overexpressed in many tumors and most 
tumors lack p73 mutations, suggest a mechanism for inactivation of p73 in human 
cancer. Despite the biochemical and in vitro studies on the physical binding of Mdm4 
and p73, thus far no studies have examined the biological significance of this 
interaction. In my thesis work, using the complicated genetic mouse models, I 
provide the first comprehensive in vivo characterization of the Mdm4 and p73 
interaction during development and tumorigenesis.  
My results reveal that loss of p73 does not rescue Mdm4-deficient early 
embryonic lethality, indicating that the unrestricted p53 activity, in absence of Mdm4 
inhibition, leads the phenotype. Interestingly, my data show that Mdm4 might inhibit 
the p73 transcriptional activity in mediating cell cycle arrest and apoptosis during 
brain development and there is a possibility that, in the absence of Mdm4, p73 
contributes to the vigorous senescent and apoptotic phenotype of p53 in embryonic 
brain. However, deletion of p73 does not rescue the Mdm4-null porencephaly 
phenotype and this phenotype is also mainly under the influence of enhanced p53 
activity. Such observation underscores that despite the well-established role of p73 
in neurogenesis, the Mdm4-p73 axis is not as significant as the Mdm4-p53 pathway 
during the CNS development. 
My tumor study also suggests a possible cooperation between Mdm4 and 
p73 during tumorigenesis, as evidenced by increased incidence of lymphoma and 
brain tumor in Mdm4Tg15 p73+/− mice compared to Mdm4Tg15 mice. Nonetheless, the 
differences in survival curve and tumor spectrum are not statistically significant, 
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implying that the dampened p53 activity due to high levels of Mdm4 is the major 
driver of spontaneous tumorigenesis in these mice and compromises the potential 
Mdm4-p73 cooperation. 
 
The Mdm4-p73 interaction during development 
 Despite the strong in vitro evidence of the Mdm4-p73 binding in the 
mammalian cells and the higher affinity of Mdm4 for p73 rather than p53 in 
biochemical studies, my in vivo studies suggest that, in the presence of enhanced 
p53 activity, such interaction does not have biological importance in embryogenesis.  
However, to ask this question in a more relevant biological system and to avoid the 
strong p53 effect in the whole embryo, I chose to examine the consequences of the 
Mmd4-p73 binding in the developing CNS.  
I found that Mdm4 inhibits the p73-mediated cell cycle arrest and apoptosis in 
embryonic brain at E14.5, as evidenced by regulation of 14-3-3σ and Perp, 
indicating that p73 contributes to Mdm4-deficiency brain tissue loss. However, the 
effect of unrestricted p53 and, subsequently, the activation of plethora of target 
genes, are much more stronger than the effect of p73 and dominates the Mdm4Δ2/Δ2 
p73−/− brain phenotype. Another explanation for the dominant phenotype of p53 is its 
expression pattern compared to p73 during CNS development. At E10.5, the 
expression of p53 is ubiquitous in mouse brain (187) while p73 is expressed 
sparsely and mostly in telencephalon (141). At later embryonic stage, p53 
expression is more heterogeneous with high levels of p53 mRNA in the ventricular 
zone neuroepithelial progenitors, telencephalon and mesencephalon, and low levels 
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in the cortical plate (187), whereas p73 is highly expressed in cortical hem, a 
structure close to hippocampus, and more specifically in CR cells (141). Thus, it 
seems reasonable to postulate that upon deletion of Mdm4, both p53 and p73 have 
increased activity as evidenced by the upregulation of their target genes, yet each 
affects distinct parts of embryonic brain. Consequently, p53 with expression in more 
regions of brain dictates the Mdm4Δ2/Δ2 p73−/− brain phenotype.  Other reason could 
be the late formation of hippocampus during embryogenesis. Although hippocampal 
molecular differentiation begins at E10.5 to E12.5, the earliest apparent hippocampal 
field differentiation is at E15.5. Thus, the time point of my study at E14.5 is relatively 
early to observe the effect of dysregulated p73 activity in hippocampal formation.  
The best way to circumvent enhanced p53 activity due to absence of Mdm4 is 
deleting p53 concomitantly. It is well known in the field that Mdm4Δ2/Δ2 p53−/− mice are 
viable with the phenotype and life span of p53−/− mice. However, the detailed 
assessment of brain anatomy, especially with respect to the regions of the brain 
wherein p73 has roles, has not been studied. For instance, whether Mdm4Δ2/Δ2 p53−/− 
mice compared to Mdm4Δ2/Δ2 p53−/− p73−/− mice have hippocampal defect or cortical 
malformation due to dysregulated p73 activity has not been examined. The 
Mdm4Δ2/Δ2 p53−/− p73−/− mice are viable, however, they die before weaning (based on 
my observation, they die approximately at P10). Thus, the best time point for such 
analyses is early postnatal days when the classic morphology of hippocampus is 
evident (188).  
 Since p73−/− mice depict the most severe phenotype in brain compared to 
TAp73−/− and ∆Np73−/− mice, it was the best genetic model to test our hypothesis. 
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However, given that N-terminal of Mdm4 binds to TA domain of p73 (167) and that 
TAp73 is more abundant than ∆Np73 in neural stem cells (172), most probably 
Mdm4 interacts with TAp73 during CNS development. My observation that cell cycle 
arrest and apoptosis is the predominant phenotype upon deletion of Mdm4 in brain 
and that TAp73 is the isoform with apoptotic and growth arrest properties (132, 134) 
also suggest that TAp73 is the major isoform in the Mdm4-p73 interaction.  To test 
this notion, it would be interesting to perform rescue study in the brain using 
TAp73+/− mice, instead of p73+/− mice. In this setting, in the absence of TAp73, 
∆Np73 is supposed to exert an inhibitory effect on p53-mediated apoptosis (137) 
and the experiment might be less confounded by the high p53 activity. Moreover, 
this experiment might shed light to the interplay of TAp73 with ∆Np73 and the 
importance of the ratio of these isoforms during CNS development, the concept that 
have been investigated in cultured neurospheres, but not in vivo and during 
embryogenesis.  
Clinical implication 
Congenital porencephaly is a rare anomaly in the neonate’s brain due to 
aberrant development of CNS (189). It is characterized as a cavity in cerebral 
hemispheres and causes severe seizures and mental retardation in patients (189). It 
is mostly sporadic and have been related to trauma and ischemic injury at mid-
gestation (190), but the observations of familial porencephaly suggested the 
genetics could also be involved in a subset of patients (191). Thus far, dysregulation 
of the Mdm4-p53 pathway have not been studied directly. However, COL4A1 is 
among the limited mutations that have been found to be associated with this 
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anomaly (192-194). Surprisingly, this gene is a p53 target gene (195), which 
indicates that p53 pathway could be activated in porencephaly. Interestingly, 
hippocampal atrophy has been reported in 95% of cases with congenital 
porencephaly (196). Such striking coexistence implies a common mechanism 
underlying both pathologies; however, it remained to be elucidated.  
Despite the prominent role of p73 during CNS development and in the 
maintenance of neural stem cells, there is still no report on the role of this gene in 
the pathogenesis of congenital brain defects. Together, the observation of 
porencephaly in Mdm4-null mice, the Mdm4-p73 interaction in developing CNS and 
the prominent role of p73 in the formation of hippocampus, suggest that it is worth 
examining the genetic alteration of Mdm4 and p73 as well as their protein-protein 
interaction in the subset of patients with porencephaly and hippocampal atrophy.  
 
The Mdm4-p73 cooperation during tumorigenesis 
 Some neoplasms such as lymphoma and brain tumor have been shown to 
harbor both Mdm4 overexpression and/or p73 loss. To address whether these two 
alterations occur within a tumor and, more specifically, if they happen in one tumor 
cell and consequently cooperate in tumor development, I used genetic mouse model 
with high expression of Mdm4 and decreased p73 gene dosage.  
 My tumor study revealed that either Mdm4 overexpression or p73 
heterozygosity is tumorigenic, which is consistent with previous studies (41, 155). 
Mdm4Tg15 p73+/− mice also developed spontaneous tumors, and, interestingly, they 
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had shorter survival, higher frequencies of lymphoma and brain tumor, as well as 
strikingly highly disseminated lymphoma compared to each individual alteration.  
Notably, Mdm4Tg15 mice in my cohort had longer survival and developed 
tumor with more latency compared to our published Mdm4Tg15 cohort study. Such 
difference between two cohorts of one transgenic mouse line might result from the 
altered pattern of transgene expression over serial breeding and across generations, 
otherwise the genetic background of both was C57BL/6 and they both had the same 
expression level of Mdm4 in MEFs (4-5 times higher than wild type MEFs) (41). On 
the other hand, p73+/− mice in my cohort had prolonged survival along with a very 
low frequency of tumorigenesis. Such discrepancy between p73+/− mice in my cohort 
and published study could be due to mouse genetic background, the factor that has 
already been shown to affect the rate and spectrum of tumor development in other 
mouse models such as p53−/− mice (197, 198). The p73+/− mice in my cohort were in 
>95% C57BL/6, whereas in the previous study these mice had mixed genetic 
background of C57BL/6 and 129/SvJae (155).  
Subsequently, such alterations in transgene expression and mouse genetic 
background also affected the survival and tumor spectrum of Mdm4Tg15 p73+/− mice 
and perhaps buffered the tumor phenotype. However, in essence, such effects made 
the interpretation of Mdm4Tg15 p73+/− tumor phenotype easier: p73 heterozygosity in 
C57BL/6 background barely develops tumors, whereas Mdm4 overexpression 
develops tumor, yet the rates of lymphoma and brain tumor are very low. However, 
the combination of both alterations results in more aggressive phenotype, higher 
incidence of severely disseminated lymphoma and higher incidence of brain tumor. 
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The presence of wild type p73 allele, as evidenced by lack of LOH, in the Mdm4Tg15 
p73+/− tumors also indicates that either Mdm4 overexpression dampens the tumor 
suppressor activity of remaining p73 allele or loss of only one allele of p73 in the 
context of high levels of Mdm4 does suffice for tumor development due to their 
collaboration through cancer signaling pathway(s).  
Since the tumor survival and tumor spectrum of Mdm4Tg15 p73+/− mice is 
highly suggestive of cooperation, yet not statistically significant, there is a possibility 
that higher level of Mdm4 would be required in order to robustly show this 
cooperation. For that, using a homozygous Mdm4 transgene and comparing 
Mdm4Tg15/Tg15 p73+/− to Mdm4Tg15/ Tg15 and p73+/− mice could be more revealing. 
Moreover, observing another tumor type in Mdm4Tg15 p73+/− mice, which is 
known, based on data from human cancer, to have altered Mdm4 and p73 would 
also be supportive. For instance, similar to lymphoma and brain tumor, the role of 
Mdm4 overexpression and loss of p73 have been well studied in breast tumors. 
Since C57BL/6 mice are resistant to mammary tumor development (199), 
unfortunately there was no chance for such observation in my model system. On the 
other hand, Balb/c mice are prone to this type of tumor (199) and, interestingly, 
Mdm4 transgenic mouse in the Balb/c genetic background develop mammary tumor 
(data from our lab). However, the p73+/− tumorigenicity in this genetic background 
has not yet been reported. It would be interesting to observe the phenotype of p73 
heterozygosity and, further, examine Mdm4Tg15 p73+/− mice in Balb/c background for 
mammary tumor formation and enhanced metastatic potential.  
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Furthermore, given that TAp73 is the isoform with tumor suppressor activity, it 
would be interesting to establish a cohort of Mdm4Tg15 TAp73+/− and Mdm4Tg15 
TAp73−/− mice to decipher this cooperation in an isoform-specific manner and also to 
understand the role of Mdm4 in regulating the ratio of both TAp73 and ∆Np73 
isoforms during tumorigenesis. 
 One potential mechanism by which this cooperation contributes to 
tumorigenesis could be genomic instability. Elevated levels of Mdm4 increase 
chromosome and chromatid breaks and delay DNA repair in a p53-independent 
manner (87). In addition, loss of p73 is also associated with genome instability (126, 
128). Thus, it is worthy to investigate whether Mdm4Tg15 p73+/− and Mdm4Tg15 p73−/− 
mice, compared to Mdm4Tg15, have higher levels of chromosome defects in tumor-
prone tissues, such as spleen and more specifically B-cells, at the pre-malignant 
stage, for example at 6-9 months old.  
 Another possible mechanism through which Mdm4 overexpression and p73 
heterozygosity could collectively enhance tumorigenicity might be E2F-1 modulation. 
The transcription factor E2F-1 mediates apoptosis and cell cycle arrest (200). p73 
has been identified as one of E2F-1 target genes and, in the absence of p53, E2F-1 
mediates apoptosis through upregulation of p73 (201). Given that Mdm4 associates 
with E2F-1 and inhibits its transcriptional activity (89), it is reasonable to postulate 
that in Mdm4Tg15 p73+/−  tumors, along with dampened p53-mediated cell death, p73-
dependent apoptosis is decreased due to E2F-1 inhibition. Another support for this 
notion is the role of E2F-1 in lymphoma and brain tumors. It has been reported that 
the low level of E2F-1 is associated with poor prognosis in patients with B-cell 
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lymphoma (202) and that E2F-1 has been considered as one the therapeutic tools in 
cancer gene therapy for brain tumors (203, 204).  
 
Clinical implication 
 A thorough investigation in The Cancer Genome Atlas (TCGA) on lymphoma, 
brain tumor, and probably breast cancer, would shed light on the coexistence of 
MDM4 and p73 alterations in tumors and, hopefully, might identify the other 
alterations as a mediator or consequence of their cooperation. The collection of such 
alterations could be used as a prognostic factor or to classify a subset of patients 
who benefit from targeted therapy. 
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CHAPTER 4. MATERIALS AND METHODS  
Mice  
Mdm4 heterozygous knockout mouse was generated in our lab (80). Mdm4∆2 
allele is the null allele of Mdm4, which is generated by deletion of exon 2 in Mdm4fx/+ 
mice, and no Mdm4 protein was detected by western blot in Mdm4∆2/∆2 p53−/− MEFs 
(80). 
Mdm4+/∆2 mice (80), p73+/− mice (155) (from Dr. Elsa Flores, MD Anderson 
Cancer Center, Houston, TX) and p53+/− (205) mice on a mixed background 
(129/SvJae and C57BL/6) were crossed to generate breeders with genotype of 
interest for the rescue (Figure 21) and gene dosage study on the whole embryo 
(Figure 22).  
Mdm4+/fx mice (80), p73+/− mice (155), and Nes-cre transgenic mice (170) 
(from Jackson laboratory) on C57BL/6 background were crossed to generate 
breeders with genotype of interest for the rescue study on developing CNS (Figure 
23).  
The day a plug was detected in females was assigned as E0.5 and the day of 
birth is defined as P0. In the first experiment of gene dosage study, mice were 
genotyped at P7; however, from P0 to P7 they were checked and counted daily.  
Mdm4Tg15 mice (41) and p73+/− mice (155), both on over 95% C57BL/6 
background, were crossed to generate the cohort for tumor study (figure 24). Mice 
were sacrificed upon moribundity or reaching 2-year time point and necropsies were 
performed.  
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Figure 21. Genetic scheme for the rescue study 
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Figure 22. Genetic scheme for the gene dosage study 
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Figure 23. Genetic scheme for the rescue study in developing CNS 
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Figure 24. Genetic scheme for establishing the cohort for tumor study 
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All mice were maintained in the mouse facility at the University of Texas M.D. 
Anderson Cancer Center in compliance with the Institutional Animal Care and Use 
Committee (IACUC) guidelines. 
In development studies, DNA was extracted from tail or yolk sac, depending 
on the developmental stage and size of embryo. In tumor study, tail snips were used 
for DNA extraction. PCR was performed using appropriate PCR primers (Table 9) 
and based on the available protocols in our laboratory.  
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Table 9. List of PCR genotyping primers 
 
Gene primer (5’  3’) 
F ctgggccgaggtggaatgtgatgt  
Mdm4fx R ggtgtccttgaacttgctgtgtagaa 
F tttccagagacatgttattatcac  
Mdm4∆2 R tagaatctggaattacagacag 
A gggccatgcctgtctacaaagaa 
B ccttctacacggatgaggtg 
 
p73 
C gaaagcgaaggagcaaagctg 
A agcgtggtggtaccttatgagc 
B ggatggtggtatactcagagcc 
 
p53 
C tcc tcg tgc ttt acg gta tc 
F ccaacagttcatgaggattcca  
Nes-cre R ttggtgtacggtcagtaaattgga 
F agggcggggttcggcttctgg  
Mdm4Tg R tcccaaaagatctccaccacagta 
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Histopathology and Immunohistochemistry 
In development studies, whole embryos were fixed in 4% paraformaldehyde 
and paraffin embedded for sagittal sectioning. In tumor studies, upon euthanasia of 
moribund mice, a complete necropsy was performed and all collected organs were 
fixed in 10% formalin for 48 hours. Fixed samples were embedded in paraffin for 
sectioning. Histological preparation of embryos and tissue samples as well as 
hematoxylin and eosin (H&E) staining were performed by the Department of 
Veterinary Medicine at the University of Texas M.D. Anderson Cancer Center. Dr. M 
James You kindly recommended the required immunohistochemical analyses and 
performed pathology on samples in tumor study. 
Immunohistochemical staining was performed on paraffin-embedded tissue 
sections as previously described (84, 166). Antibodies used for 
immunohistochemistry were: Ki67, 1:100 (ab16667, Abcam, Cambridge, MA, USA); 
caspase 3, 1:200 (9661S, Cell Signaling Technology, Danvers, MA, USA);  
CD45R/B220, 1:50 (Clone RA3-6B2 (RUO), BD Pharmingen, San Diego, CA, USA); 
CD3, 1:100 (ab5690, Abcam, Cambridge, MA, USA; Lysozyme, 1:1000 (NBP1-
95509, Novus, Cambridge, UK). 
Subsequently, stained sections were detected with Vectastain Elite ABC Reagent 
and Vector DAB substrate (Vector Laboratories, Burlingame, CA, USA) and 
counterstained with nuclear fast red (Vector Laboratories). 
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LOH analyses 
A small section of tumor or tumoral foci were dissected and frozen for tumor 
DNA extraction. PCR was performed for detecting wild type and null alleles of p73. 
 
Real-Time qRT-PCR 
Total RNAs were isolated from MEFs or embryonic brain at E14.5 using 
TRIzol reagent (Invitrogen, Carlsbad, CA, USA), treated with DNase (Roche Life 
Science, Indianapolis, IN, USA), and then reverse transcribed by using First-Strand 
cDNA Synthesis Kit (GE Healthcare, Piscataway, NJ, USA) following manufacturer’s 
instructions. Quantitative real-time PCR was performed on a 7900HT Fast Real-time 
PCR system (Applied Biosystems) according to the manufacturer’s instructions (Bio-
Rad, Valencia, CA, USA). Expression was normalized to the Rplp0 levels. Primer 
sequences are in Table 10. 
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Table 10. List of primers used for Real-Time PCR 
 
Gene primer (5’  3’) 
F CAGGCACCATGTCCAATCCT  
p21  
 R GAGACAACGGCACACTTTGCT 
F TGAACATTTCACCTTGCGCACCTG  
 
Mdm4 R CAACATCTGACAGTGCTTGCAGGA 
F GCTGCAGCCACGCTTTTC 
 
 
Perp  
 R GGCGAAGAACGAGAGAATGAA 
 
F TGGCCACTGGCGATGAC 
 
 
14-3-3σ 
 
R GGCTGACCGGGCAGAAT 
 
F GGCATTGTGGATGAGTGTTG  
p57 
 R TCTCCTTTGCAGCTTCGTTT 
F AGTCCCAAGGAGAAAAACCGA  
Hes5 
 R GCTGTGTTTCAGGTAGCTGAC 
F ATGTGGACGAGTGTCTGTTGC  
Notch2 
 R GGAAGCATAGGCACAGTCATC 
F CAAAGTGTGCCTCAAGGAGTATCAG  
Jag1 
 R TCCACCAGCAAAGTGTAGGACCTC 
F CAGTGCAAAAACTTCACACCGCCGC 
 
 
Jag2 
 R GGAGCAGCTGGGGTCTTTGGTG 
F CCCTGAAGTGCTCGACATCA 
 
 
Rplp0  
 R TGCGGACACCCTCCAGAA 
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Statistical Analyses  
All statistical analyses were performed using GraphPad Prism software (La 
Jolla, CA, USA) and a p-value of <0.05 was considered statistically significant. The 
difference between observed and expected frequencies of embryos was determined 
by chi-square test. The multiple comparisons test for gene expression analyses of 
embryonic brain was performed by ANOVA using Newman-Keuls posttest. The 
difference between survival curves was determined by using Log-rank (Mantel-Cox) 
test and the difference of the tumor spectrum of each group of mice was analyzed by 
Fisher’s exact test. 
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